Ebola Hemorrhagic Fever Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Dose-Escalation A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers
The purpose of this study is to evaluate the safety and tolerability of healthy male and female subjects with intravenous (IV) infusions of AVI 7537 compared to matched placebo in and to evaluate the pharmacokinetics (PK).
The purpose of this study is to evaluate the safety and tolerability of 14 once daily
intravenous (IV) infusions of ascending doses of AVI 7537 compared to matched placebo in
healthy male and female subjects.
To evaluate the pharmacokinetics (PK) of 14 once daily doses of AVI-7537 in healthy male and
female subjects
;
Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00374309 -
Experimental Vaccine for Prevention of Ebola Virus Infection
|
Phase 1 | |
| Completed |
NCT02911415 -
Open Study of the Duration of Immunity After Vaccination With GamEvac-Combi
|
N/A | |
| Completed |
NCT01353027 -
Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus
|
Phase 1 |